The Global Antacids Market Size accounted for USD 7.2 Billion in 2023 and is estimated to achieve a market size of USD 10.9 Billion by 2032 growing at a CAGR of 4.8% from 2024 to 2032.
Antacids Market (By Drug Class: Proton Pump Inhibitors, H2-Receptor Antagonists, and Acid Neutralizers; By Formulation Type: Tablet, Liquid, Powder, and Others; By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy; and By Region: North America, Europe, Asia-Pacific, Latin America, and the MEA)
Antacids Market Highlights
- The global antacids market revenue is projected to reach USD 10.9 billion by 2032, with a CAGR of 4.8% from 2024 to 2032
- The North America antacids market was valued at approximately USD 3.2 billion in 2023
- The Asia Pacific antacids market is expected to grow at a CAGR of over 5.6% from 2024 to 2032
- In 2023, the proton pump inhibitors sub-segment held a significant market share among drug classes
- The tablet formulation sub-segment also accounted for a notable market share in 2023
- Increasing awareness about digestive health and self-medication is the antacids market trend that fuels the industry demand
Changing dietary preferences are projected to fuel market expansion in the future years. Furthermore, inconsistent eating and sleeping patterns are anticipated to contribute to increasing acidity in the population, hence accelerating market expansion. The increased prevalence of Gastroesophageal Reflux Disease (GERD) is expected to have a considerable market impact in the forecast year. For instance, according to National Institute of Health, GERD is a prevalent gastrointestinal illness that affects approximately 20% of individuals in Western countries. The incidence in the United States ranges from 18.1% to 27.8%, with men having a slightly higher rate.
Global Antacids Market Dynamics
Market Drivers
- Increasing prevalence of gastrointestinal disorders
- Rising consumption of processed and fast foods
- Growing awareness about digestive health
Market Restraints
- Side effects and long-term health risks of antacid use
- Growing popularity of alternative therapies and natural remedies
- Stringent regulatory standards and potential for market saturation
Market Opportunities
- Innovations in antacid formulations and delivery systems
- Expanding markets in developing regions with rising healthcare access
- Increasing demand for over-the-counter medications and self-medication
Antacids Market Report Coverage
Market |
Antacids Market |
Antacids Market Size 2022 |
USD 7.2 Billion
|
Antacids Market Forecast 2032 |
USD 10.9 Billion |
Antacids Market CAGR During 2023 - 2032 |
4.8% |
Antacids Market Analysis Period |
2020 - 2032 |
Antacids Market Base Year
|
2022 |
Antacids Market Forecast Data |
2023 - 2032 |
Segments Covered |
By Drug Class, By Formulation Type, By Distribution Channel, And By Geography
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled |
Sun Pharmaceuticals Ltd, Reckitt Benckiser Group plc, GGlaxoSmithKline plc, Pfizer Inc., Bayer AG, Sanofi, BoehringerIngelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Procter & Gamble and Takeda Pharmaceutical Company Limited. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Antacids Market Insights
The rising use of processed and fast foods, which are generally high in fats and carbohydrates, has resulted in an increase in gastrointestinal problems such acid reflux and heartburn. For instance, according to Indian Council for Research on International Economic Relations (ICRIER), the value of ultra-processed retail sales climbed rapidly, from 14% in 2011 to 18% in 2020 and 19% in 2021. The growing rate of processed and necessary foods outpaces that of GDP. Ultra processed foods are expected to grow faster than essential foods. The increasing prevalence of digestive discomfort is driving up demand for antacids, which neutralize stomach acid and provide relief. As eating patterns continue to emphasize convenience and indulgence above balanced nutrition, the antacids industry is expanding significantly.
The increased popularity of alternative medicines and natural remedies is limiting the antacids business. For instance, the World Health Organization (WHO) is hosting the Traditional Medicine Global Summit on August 17-18, 2023 in Gandhinagar, Gujarat, India to promote progress in global health and sustainability. To cure acid-related diseases, consumers are increasingly turning to natural remedies such as herbal supplements and dietary adjustments. As a result, traditional antacids are losing popularity as more people seek towards other remedies.
The rising trend in self-medication and the growing demand for over-the-counter (OTC) medications are creating significant opportunities for the antacids market. For instance, Wonderbelly, an Austin-based firm, was launched in June 2022 with over-the-counter (OTC) chewable antacid tablets in flavors like strawberry milkshake, watermelon mint, and fruity cereal. Consumers increasingly prefer OTC solutions for managing common digestive issues, driving the need for more accessible and effective antacid products. This shift towards self-care is fueled by the desire for convenience and cost-effectiveness, which further boosts market growth.
Antacids Market Segmentation
The worldwide market for antacids is split based on drug class, formulation type, distribution channel, and geography.
Antacid Market By Drug Class
- Proton Pump Inhibitors
- H2-Receptor Antagonists
- Acid Neutralizers
According to the antacids industry analysis, proton pump inhibitors (PPIs) dominate the market because they are more effective in reducing stomach acid production than other antacids. They provide long-term treatment from illnesses such as gastroesophageal reflux disease (GERD) and peptic ulcers by targeting acid-producing pumps in the stomach lining. Furthermore, their demonstrated effectiveness and extended duration of action have solidified their market leadership.
Antacid Market By Formulation Type
- Tablet
- Liquid
- Powder
- Others
The tablet segment is the largest formulation type category in the antacids market and it is expected to increase over the industry. The availability of chewable tablets in various flavors enhances patient adherence to medication, which is expected to contribute to the segment's growth. Tablets provide precise dosing compared to other forms and are easy to store, factors that will likely drive segment growth in the coming years. Additionally, the introduction of new products by major players is expected to further boost the segment.
Antacid Market By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
According to the antacids market forecast, retail pharmacies are expected to lead the market throughout 2024 to 2032 because they are widely accessible and convenient, providing consumers with simple access to over-the-counter (OTC) drugs. They frequently offer a wide range of brands and formulations to meet the interests and demands of specific customers. Furthermore, retail pharmacies benefit from high client trust and the opportunity to offer individualized advice. Because of their accessibility and range, they are a better option for purchasing antacids than other distribution methods.
Antacids Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Antacids Market Regional Analysis
For several reasons, North America dominates antacids market, owing to the increasing frequency of digestive diseases and consumer awareness of antacid products. The region's strengthening healthcare system, as well as increased investments by industry players, is projected to help drive growth. For instance, according to American Medical Association, in 2022, health-care spending in the United States rose by 4.1% to $4.5 trillion, or $13,493 per person. This growth rate is comparable to the pre-pandemic rate (4.1% in 2019). Furthermore, the presence of developed economies in the region promotes growth.
The Asia-Pacific region is projected to be the fastest-growing segment in the forecast years, owing to significant unmet clinical requirements, the availability of effective treatment modalities, and higher consumer awareness of these products. Furthermore, the presence of prominent companies such as Pfizer Inc., GGlaxoSmithKline plc., and Abbott is expected to propel market growth in the future years. For instance, in 2022, Zydus Lifesciences received FDA approval to market Famotidine tablets, a histamine H2 receptor blocker that greatly lowers stomach acid production.
Antacids Market Players
Some of the top antacids companies offered in our report include Bayer AG, BoehringerIngelheim International GmbH, Sun Pharmaceuticals Ltd, Reckitt Benckiser Group plc, GlaxoSmithKline plc, Pfizer Inc., Sanofi, Dr. Reddy’s Laboratories Ltd., Procter & Gamble and Takeda Pharmaceutical Company Limited.
CHAPTER 1. Industry Overview of Antacids Market
1.1. Definition and Scope
1.1.1. Definition of Antacids
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Antacids Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Antacids Market By Drug Class
1.2.3. Antacids Market By Formulation Type
1.2.4. Antacids Market By Distribution Channel
1.2.5. Antacids Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.1.3. Driver 3
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.2.3. Restraint 3
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.3.3. Opportunity 3
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Antacids Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Antacids Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2023
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2023
4.2. R&D Status of Major Manufacturers in 2023
CHAPTER 5. Antacids Market By Drug Class
5.1. Introduction
5.2. Antacids Revenue By Drug Class
5.2.1. Antacids Revenue (USD Billion) and Forecast, By Drug Class, 2020-2032
5.2.2. Proton Pump Inhibitors
5.2.2.1. Proton Pump Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. H2-Receptor Antagonists
5.2.3.1. H2-Receptor Antagonists Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Acid Neutralizers
5.2.4.1. Acid Neutralizers Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Antacids Market By Formulation Type
6.1. Introduction
6.2. Antacids Revenue By Formulation Type
6.2.1. Antacids Revenue (USD Billion) and Forecast, By Formulation Type, 2020-2032
6.2.2. Tablet
6.2.2.1. Tablet Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Liquid
6.2.3.1. Liquid Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Powder
6.2.4.1. Powder Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Others
6.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Antacids Market By Distribution Channel
7.1. Introduction
7.2. Antacids Revenue By Distribution Channel
7.2.1. Antacids Revenue (USD Billion) and Forecast, By Distribution Channel, 2020-2032
7.2.2. Retail Pharmacy
7.2.2.1. Retail Pharmacy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Hospital Pharmacy
7.2.3.1. Hospital Pharmacy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Online Pharmacy
7.2.4.1. Online Pharmacy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Antacids Market By Country
8.1. North America Antacids Market Overview
8.2. U.S.
8.2.1. U.S. Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.2.2. U.S. Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
8.2.3. U.S. Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.3. Canada
8.3.1. Canada Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.3.2. Canada Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
8.3.3. Canada Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Antacids Market By Country
9.1. Europe Antacids Market Overview
9.2. U.K.
9.2.1. U.K. Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.2.2. U.K. Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
9.2.3. U.K. Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.3. Germany
9.3.1. Germany Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.3.2. Germany Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
9.3.3. Germany Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.4. France
9.4.1. France Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.4.2. France Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
9.4.3. France Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.5. Spain
9.5.1. Spain Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.5.2. Spain Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
9.5.3. Spain Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.6.2. Rest of Europe Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
9.6.3. Rest of Europe Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Antacids Market By Country
10.1. Asia Pacific Antacids Market Overview
10.2. China
10.2.1. China Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.2.2. China Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
10.2.3. China Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.3. Japan
10.3.1. Japan Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.3.2. Japan Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
10.3.3. Japan Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.4. India
10.4.1. India Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.4.2. India Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
10.4.3. India Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.5. Australia
10.5.1. Australia Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.5.2. Australia Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
10.5.3. Australia Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.6. South Korea
10.6.1. South Korea Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.6.2. South Korea Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
10.6.3. South Korea Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.7.2. Rest of Asia-Pacific Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
10.7.3. Rest of Asia-Pacific Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Antacids Market By Country
11.1. Latin America Antacids Market Overview
11.2. Brazil
11.2.1. Brazil Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.2.2. Brazil Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
11.2.3. Brazil Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.3. Mexico
11.3.1. Mexico Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.3.2. Mexico Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
11.3.3. Mexico Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Latin America Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
11.4.3. Rest of Latin America Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Antacids Market By Country
12.1. Middle East & Africa Antacids Market Overview
12.2. GCC
12.2.1. GCC Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.2.2. GCC Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
12.2.3. GCC Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.3. South Africa
12.3.1. South Africa Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.3.2. South Africa Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
12.3.3. South Africa Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Antacids Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.4.2. Rest of Middle East & Africa Antacids Revenue (USD Billion) and Forecast By Formulation Type, 2020-2032
12.4.3. Rest of Middle East & Africa Antacids Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Antacids Market
13.1. Antacids Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Antacids Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Sun Pharmaceuticals Ltd
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2023
14.1.3.2. Sun Pharmaceuticals Ltd. 2023 Antacids Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Reckitt Benckiser Group plc
14.3. GlaxoSmithKline plc
14.4. Pfizer Inc.
14.5. Bayer AG
14.6. Sanofi
14.7. BoehringerIngelheim International GmbH
14.8. Dr. Reddy’s Laboratories Ltd.
14.9. Procter & Gamble
14.10. Takeda Pharmaceutical Company Limited